Patient Characteristics
| Pt group | Pt no. | Sex | Age | PLC | Tx interval before PET scan | MDT (mm) | 18F-FDG | 18F-FLT | Pathology | 18F-FDG | 18F-FLT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNM stage | Treatment status | Max SUV tumor | Mean SUV tumor | TNT | Max SUV tumor | Mean SUV tumor | TNT | ||||||||||||||
| Suspected recurrent laryngeal cancer | 1 | F | 52 | T2N0 | RTX | 6 mo | NA | − | + | Inflammation | NA | NA | NA | 1.4 | 1.1 | 1.1 | |||||
| 2 | M | 64 | T1N0 | RTX | 9y | NA | − | − | No abnormalities | NA | NA | NA | NA | NA | NA | ||||||
| 3 | M | 56 | T3N2c | Follow-up† | 3 mo | 1.8 | + | + | RLC | 3.2 | 2.8 | 1.5 | 1.2 | 1.1 | 1.2 | ||||||
| 4 | M | 70 | T1a/CISN0 | CO2 laser | 6y | NA* | + | + | RLC | 1.9 | 1.5 | 1.5 | 1.5 | 1.2 | 1.5 | ||||||
| 5 | M | 65 | T2N0 | RTX | 9 mo | 18 | + | + | RLC | 3.0 | 2.3 | 1.5 | 1.3 | 1.1 | 1.4 | ||||||
| 6 | M | 50 | T2N0 | RTX | 10 mo | 15 | + | + | RLC | 8.5 | 6.5 | 4.1 | 2.9 | 1.9 | 3.2 | ||||||
| 7 | M | 58 | T1N0 | RTX | 1.5 mo | 40 | + | + | RLC | 3.7 | 2.9 | 2.4 | 1.5 | 1.3 | 1.4 | ||||||
| 8 | M | 66 | T4N0 | RTX | 3 mo | 20 | + | + | RLC | 3.3 | 2.6 | 1.4 | 1.9 | 1.4 | 1.4 | ||||||
| 9 | M | 56 | T3N1 | RTX | 16 mo | 17 | + | + | RLC | 2.9 | 2.2 | 1.4 | 1.0 | 0.8 | 1.1 | ||||||
| 10 | M | 65 | T1aN0 | CO2 laser | 13 mo | NA | + | + | No abnormalities | 1.9 | 1.6 | 1.3 | 1.5 | 1.2 | 1.1 | ||||||
| 11 | M | 55 | T2N0 | RTX | 5 mo | NA | − | − | Inflammation | NA | NA | NA | NA | NA | NA | ||||||
| Primary laryngeal cancer | 12 | M | 79 | T2N0 | RTX | NA | NA* | + | + | PLC | 2.5 | 1.8 | 1.3 | 1.7 | 1.2 | 1.7 | |||||
| 13 | M | 72 | T3-4N0 | RTX | NA | NA* | + | + | PLC | 5.8 | 4.4 | 3.1 | 5.7 | 3.8 | 3.5 | ||||||
| 14 | M | 66 | T1aN0 | RTX | NA | NA* | − | − | PLC | NA | NA | NA | NA | NA | NA | ||||||
| 15 | M | 55 | T2N0 | RTX | NA | NA* | + | + | PLC | 6.2 | 4.8 | 2.8 | 3.2 | 2.0 | 2.2 | ||||||
| 16 | M | 65 | T4N0 | RTX | NA | NA* | + | + | PLC | 5.8 | 4.4 | 2.3 | 3.7 | 2.6 | 2.2 | ||||||
| 17 | M | 79 | T4N0 | RTX | NA | NA* | + | + | PLC | 3.2 | 2.5 | 2.8 | 2.3 | 1.9 | 1.9 | ||||||
| 18 | M | 64 | T1aN0 | RTX | NA | NA* | + | + | PLC | 2.1 | 1.6 | 1.3 | 1.2 | 0.9 | 1.5 | ||||||
| 19 | M | 72 | T1bN0 | RTX | NA | NA* | − | − | PLC | NA | NA | NA | NA | NA | NA | ||||||
| 20 | M | 53 | T2N0 | RTX | NA | NA* | + | + | PLC | 3.8 | 2.8 | 4.7 | 1.6 | 1.2 | 2.0 | ||||||
| 21 | M | 81 | T2bN0 | RTX | NA | NA* | + | + | PLC | 4.6 | 3.5 | 2.9 | 1.6 | 1.1 | 1.6 | ||||||
↵* Only biopsies performed.
↵† Follow-up instead of RTX because of primary treatment of lung cancer.
PLC = primary laryngeal cancer; Tx interval = time interval between therapy of primary laryngeal cancer and PET scan; MDT = maximum diameter of the tumor; RTX = radiation therapy; NA = not applicable; − = negative; + = positive; RLC = recurrent laryngeal cancer.